Repeated injections in the exact same spot can cause lipohypertrophy, where fatty tissue changes texture and affects absorption
The study included substantial preclinical work and a small proof-of-concept human component, so it should not be generalized to every older, frail, or medically complex patient
Retatrutides Phase 3 TRIUMPH-4 trial, published in December 2025, showed participants on the 12mg dose lost an average of 28.7% of their body weight over 68 weeks, with nearly 40% of participants losing 30% or more
however, cellular mechanisms related to the central nervous system, particularly glial cell dysfunction associated with astrocytes and microglia [25, 26] are among the most commonly proposed underlying explanations [4, 27, 28]
Semaglutide versus tirzepatide Tirzepatide represents the next evolution beyond semaglutide
These treatments work well for refining results but have limitations